Dr Stanley Ngare.  Pharmacology of Types of insulin available  Various routes of delivery & factors that affect absorption  Patient and provider barriers.

Slides:



Advertisements
Similar presentations
Abstract Objective: Intensive insulin management (IIM) improves glycemic control, and lowers the risks of long-term microvascular complications. In children,
Advertisements

Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Diabetes in Young Women Francine R. Kaufman, M.D. Professor of Pediatrics The Keck School of Medicine of USC Head, Center for Diabetes and Endocrinology.
Insulin Therapy. Insulin Treatment (when?) Any Glucose Level Age Rapid onset Weight loss Tablets fail Pregnancy Illness Ketoacidosis Pancreat-ectomy.
PREVENTION AND CARE OF DIABETES MELLITUS BY, DR. REKHA DUTT Associate professor, Department of PSM Padmashree DR. D.Y.Patil Medical College, Nerul,Navi.
In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
Canadian Diabetes Association Clinical Practice Guidelines Monitoring for Glycemic Control Chapter 9 Lori Berard, Ian Blumer, Robyn Houlden, David Miller,
INSULININJECTIONINSULININJECTION Multiple Insulin Injection Therapy.
Insulin Diabetes Outreach (June 2011). 2 Insulin Learning outcomes >Understand the difference between insulin therapy in type 1 diabetes as compared to.
Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,
Diabetes.. Definition. The term of diabetes describes several syndromes of abnormal carbohydrates metabolism that are characterized by hyperglycemia.
Correction Insulin for Inpatient Hyperglycemia Estelle Lin June 2012.
Dr. A. R. GOHARIAN Endocrinologist
Insulin therapy.
INSULIN THERAPY IN TYPE 1 DIABETES
Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes Technology Update
GDM DIAGNOSIS AND MANAGEMENT
Presented by Dr. Soe Sandi Tint
Basal and Meal Time Insulin Case Study
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.
5/26/2016 8:44 AM Reviewing Carbohydrates. 5/26/2016 8:44 AM Functions of Carbohydrates Why do we need them? Provide Energy Spare Protein Promote Normal.
Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar.
Davida F. Kruger, MSN,APN-BC,BC-ADM Certified Nurse Practitioner Division of Endocrinology, Diabetes, Bone and Mineral Disorders Henry Ford Health System.
Glucose Control and Monitoring
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA Part 4.
New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Identify barriers to effective patient teaching. Identify and teach to the standards of medical care for the management of Type 2 diabetes Describe the.
Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
Prevention of Diabetes, Can we?. EP Joslin, 1921 “…… it is proper at the present time to devote time not alone to treatment, but still more, as in the.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Insulin initiation in Type 2 Diabetes
Diabetes Mellitus Part 2 Kathy Martin DNP, RN, CNE.
Monitoring and Management Jennifer Danielson, PharmD, MBA, CDE Clinical Assistant Professor University of Washington School of Pharmacy.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
Insulin Type (trade name)
Pharmacy Protocol for Insulin Dosing in the Hospitalized Patient
Baseline characteristics
EndoTool IV Physician User Guide Content Expert:
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood
Endocrine System KNH 411.
Drugs for Diabetes Mellitus
Endocrine System KNH 411.
T1DM: Insulin Initiation
Figure 4 Amino acid structure of short-acting and long-acting insulins
New Patient-Friendly Options for Managing Insulin Dosing
Overview of Disparities
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Diabetes.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Endocrine System KNH 411.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.
Modern Advances in Glucose Monitoring
Figure 3 Pharmacodynamic action profiles of long-acting insulins
Managing Hypoglycemia & Hyperglycemia
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Insulin Delivery Systems Atlanta Diabetes Associates
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Dr Stanley Ngare

 Pharmacology of Types of insulin available  Various routes of delivery & factors that affect absorption  Patient and provider barriers  Treatment should be individualised  Challenges in monitoring blood glucose  Complications of insulin therapy.

 Pre Type 1 DM: Was an acute terminal illness  Insulin changed this: Saved lives = chronic illness  Now: Helps achieve glycemic control hence delay or prevent microvascular complications ?prevent macrovascular complications

1. Rapid acting Analogues (insulin like) 2. Short acting /soluble/ regular 3. Intermediate acting  Isophane (NPH- Neutral Protamine Hegadorn) 4. Long acting (Analogues)  Glargine  Detemir

 Single most important “ medical” barrier to glycaemia : ▪ HYPOGLYCEMIA  Single most important “ Patient &provider barrier” to glycaemia: PSYCHOLOGICAL “ INSULIN RESISTANCE”

 All people with Type 1 Diabetes  Many Type 2 Diabetic patients  Pregnancy  Inpatient care

 Calculate the TDD Type 1 (0.6) UI kg/day Type UI kg/day  Some conditions may require higher or less doses e.g obesity, puberty, hypoglycemia unawareness.  Progressive adjust insulin to target  SMBG ( Glucometer) Essential tool

 Appreciation Mr Michael Brown -CDE